First results of the SOAP project. Open access publishing in 2010

The SOAP (Study of Open Access Publishing) project has compiled data on the present offer for open access publishing in online peer-reviewed journals. Starting from the Directory of Open Access Journals, several sources of data are considered, including inspection of journal web site and direct inquiries within the publishing industry. Several results are derived and discussed, together with their correlations: the number of open access journals and articles; their subject area; the starting date of open access journals; the size and business models of open access publishers; the licensing models; the presence of an impact factor; the uptake of hybrid open access.Comment: Submitted to PLoS ON

Highlights from the SOAP project survey. What Scientists Think about Open Access Publishing

The SOAP (Study of Open Access Publishing) project has run a large-scale survey of the attitudes of researchers on, and the experiences with, open access publishing. Around forty thousands answers were collected across disciplines and around the world, showing an overwhelming support for the idea of open access, while highlighting funding and (perceived) quality as the main barriers to publishing in open access journals. This article serves as an introduction to the survey and presents this and other highlights from a preliminary analysis of the survey responses. To allow a maximal re-use of the information collected by this survey, the data are hereby released under a CC0 waiver, so to allow libraries, publishers, funding agencies and academics to further analyse risks and opportunities, drivers and barriers, in the transition to open access publishing.Comment: Data manual available at http://bit.ly/gI8nct Compressed CSV data file available at http://bit.ly/gSmm71 Alternative data formats: CSV http://bit.ly/ejuvKO XLS http://bit.ly/e6gE7o XLSX http://bit.ly/gTjyv

Open access journals – what publishers offer, what researchers want

The SOAP (Study of Open Access Publishing) project has analyzed the current supply and demand situation in the open access journal landscape. Starting from the Directory of Open Access Journals, several sources of data were considered, including journal websites and direct inquiries within the publishing industry to comprehensively map the present supply of online peer-reviewed OA journals. The demand for open access publishing is summarised, as assessed through a large-scale survey of researchers' opinions and attitudes. Some forty thousand answers were collected across disciplines and around the world, reflecting major support for the idea of open access, while highlighting drivers of and barriers to open access publishing

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.

Background: The inhibition of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) is a potential synthetic lethal therapeutic strategy for the treatment of cancers with specific DNA-repair defects, including those arising in carriers of a BRCA1 or BRCA2 mutation. We conducted a clinical evaluation in humans of olaparib (AZD2281), a novel, potent, orally active PARP inhibitor. Methods: This was a phase 1 trial that included the analysis of pharmacokinetic and pharmacodynamic characteristics of olaparib. Selection was aimed at having a study population enriched in carriers of a BRCA1 or BRCA2 mutation. Results: We enrolled and treated 60 patients; 22 were carriers of a BRCA1 or BRCA2 mutation and 1 had a strong family history of BRCA-associated cancer but declined to undergo mutational testing. The olaparib dose and schedule were increased from 10 mg daily for 2 of every 3 weeks to 600 mg twice daily continuously. Reversible dose-limiting toxicity was seen in one of eight patients receiving 400 mg twice daily (grade 3 mood alteration and fatigue) and two of five patients receiving 600 mg twice daily (grade 4 thrombocytopenia and grade 3 somnolence). This led us to enroll another cohort, consisting only of carriers of a BRCA1 or BRCA2 mutation, to receive olaparib at a dose of 200 mg twice daily. Other adverse effects included mild gastrointestinal symptoms. There was no obvious increase in adverse effects seen in the mutation carriers. Pharmacokinetic data indicated rapid absorption and elimination; pharmacodynamic studies confirmed PARP inhibition in surrogate samples (of peripheral-blood mononuclear cells and plucked eyebrow-hair follicles) and tumor tissue. Objective antitumor activity was reported only in mutation carriers, all of whom had ovarian, breast, or prostate cancer and had received multiple treatment regimens. Conclusions: Olaparib has few of the adverse effects of conventional chemotherapy, inhibits PARP, and has antitumor activity in cancer associated with the BRCA1 or BRCA2 mutation. (ClinicalTrials.gov number, NCT00516373.) N Engl J Med 2009;361:123-34

First results of the SOAP Project

* About the project * Highlights: Gold OA journals today * Results from the large-scale survey of researcher

First results of the FP7 SOAP Project

* About the project * Highlights: Gold OA journals today * Results from the large-scale survey of researcher